These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 32846899

  • 1. Structural Insight into CVB3-VLP Non-Adjuvanted Vaccine.
    Hankaniemi MM, Baikoghli MA, Stone VM, Xing L, Väätäinen O, Soppela S, Sioofy-Khojine A, Saarinen NVV, Ou T, Anson B, Hyöty H, Marjomäki V, Flodström-Tullberg M, Cheng RH, Hytönen VP, Laitinen OH.
    Microorganisms; 2020 Aug 24; 8(9):. PubMed ID: 32846899
    [Abstract] [Full Text] [Related]

  • 2. Formalin treatment increases the stability and immunogenicity of coxsackievirus B1 VLP vaccine.
    Hankaniemi MM, Stone VM, Andrejeff T, Heinimäki S, Sioofy-Khojine AB, Marjomäki V, Hyöty H, Blazevic V, Flodström-Tullberg M, Hytönen VP, Laitinen OH.
    Antiviral Res; 2019 Nov 24; 171():104595. PubMed ID: 31491431
    [Abstract] [Full Text] [Related]

  • 3. A 3.0-Angstrom Resolution Cryo-Electron Microscopy Structure and Antigenic Sites of Coxsackievirus A6-Like Particles.
    Chen J, Zhang C, Zhou Y, Zhang X, Shen C, Ye X, Jiang W, Huang Z, Cong Y.
    J Virol; 2018 Jan 15; 92(2):. PubMed ID: 29093091
    [Abstract] [Full Text] [Related]

  • 4. Coxsackievirus B3 VLPs purified by ion exchange chromatography elicit strong immune responses in mice.
    Koho T, Koivunen MR, Oikarinen S, Kummola L, Mäkinen S, Mähönen AJ, Sioofy-Khojine A, Marjomäki V, Kazmertsuk A, Junttila I, Kulomaa MS, Hyöty H, Hytönen VP, Laitinen OH.
    Antiviral Res; 2014 Apr 15; 104():93-101. PubMed ID: 24485896
    [Abstract] [Full Text] [Related]

  • 5. Vaccination with coxsackievirus B3 virus-like particles elicits humoral immune response and protects mice against myocarditis.
    Zhang L, Parham NJ, Zhang F, Aasa-Chapman M, Gould EA, Zhang H.
    Vaccine; 2012 Mar 16; 30(13):2301-8. PubMed ID: 22306858
    [Abstract] [Full Text] [Related]

  • 6. Combination of three virus-derived nanoparticles as a vaccine against enteric pathogens; enterovirus, norovirus and rotavirus.
    Heinimäki S, Hankaniemi MM, Sioofy-Khojine AB, Laitinen OH, Hyöty H, Hytönen VP, Vesikari T, Blazevic V.
    Vaccine; 2019 Dec 03; 37(51):7509-7518. PubMed ID: 31585726
    [Abstract] [Full Text] [Related]

  • 7. Comparison of structure and immunogenicity of CVB1-VLP and inactivated CVB1 vaccine candidates.
    Soppela S, Plavec Z, Gröhn S, Jartti M, Oikarinen S, Laajala M, Marjomaki V, Butcher SJ, Hankaniemi MM.
    Res Sq; 2024 Jun 28. PubMed ID: 38978565
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.
    Schweneker M, Laimbacher AS, Zimmer G, Wagner S, Schraner EM, Wolferstätter M, Klingenberg M, Dirmeier U, Steigerwald R, Lauterbach H, Hochrein H, Chaplin P, Suter M, Hausmann J.
    J Virol; 2017 Jun 01; 91(11):. PubMed ID: 28331098
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Immunogenicity and performance of an enterovirus 71 virus-like-particle vaccine in nonhuman primates.
    Lim PY, Hickey AC, Jamiluddin MF, Hamid S, Kramer J, Santos R, Bossart KN, Cardosa MJ.
    Vaccine; 2015 Nov 04; 33(44):6017-24. PubMed ID: 26271825
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A single intranasal administration of virus-like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus.
    Jiao YY, Fu YH, Yan YF, Hua Y, Ma Y, Zhang XJ, Song JD, Peng XL, Huang J, Hong T, He JS.
    Antiviral Res; 2017 Aug 04; 144():57-69. PubMed ID: 28529001
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Development of Virus-Like-Particle Vaccine and Reporter Assay for Zika Virus.
    Garg H, Sedano M, Plata G, Punke EB, Joshi A.
    J Virol; 2017 Oct 15; 91(20):. PubMed ID: 28794019
    [Abstract] [Full Text] [Related]

  • 19. Efficient expression of enterovirus 71 based on virus-like particles vaccine.
    Kim HJ, Son HS, Lee SW, Yoon Y, Hyeon JY, Chung GT, Lee JW, Yoo JS.
    PLoS One; 2019 Oct 15; 14(3):e0210477. PubMed ID: 30845175
    [Abstract] [Full Text] [Related]

  • 20. Lactogenic antibody responses in cows vaccinated with recombinant bovine rotavirus-like particles (VLPs) of two serotypes or inactivated bovine rotavirus vaccines.
    Kim Y, Nielsen PR, Hodgins D, Chang KO, Saif LJ.
    Vaccine; 2002 Jan 15; 20(7-8):1248-58. PubMed ID: 11803088
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.